Track topics on Twitter Track topics that are important to you
EATONTOWN, NJ -- (Marketwired) -- 07/22/15 --
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the further expansion of its global footprint of its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT adipose tissue (fat) processing and storage technologies with Cell Source (CS), a Japan based corporation. CS currently operates a cellular processing and banking facility along with an established chain of surgery centers, offering cosmetic, plastic and orthopedic procedures to patients throughout Japan.
American CryoStem has licensed to CS the rights to utilize the Company's Standard Operating Procedures (SOP's) to create and market the Company's ATGRAFT tissue storage service in Japan. The financial terms call for an upfront licensing fee, annual minimum licensing payments and the purchase of CRYO's ACSelerate non-DMSO cryogenic tissue storage media and Cellect tissue collection kit and other required consumables for sample processing. Upon execution, CRYO received the first year annual licensing fee.
"We are pleased to announce another international licensing agreement for our ATGRAFT tissue storage platform. This agreement will be the second licensing agreement and the third laboratory facility utilizing CRYO's technology in the Asian market. This license furthers our corporate mission to establish a global network of laboratories operating under a standardized platform and utilizing our consumables for processing," commented John Arnone, CEO of American CryoStem.
John Arnone further commented, "Working in the Japanese market presents an exciting opportunity for our technology to provide the foundational tissue processing and cryopreservation support platform required for the advancement of their rapidly expanding Regenerative Medicine and Cell Therapy market. This phase 1 licensing agreement covers the collection, processing and storage of adipose tissue, allowing our partners to grow and establish a presence in the market with the opportunity to take advantage of our full multi-phase stem cell expansion and differentiation platform in the future."
Masato Tsumamoto, COO of Cell Source, commented, "The technology provided by American CryoStem serves as the initial step towards establishing our Company as the premier provider of high quality collected, processed and cryopreserved adipose tissue for aesthetic procedures and future therapeutic uses. The promise of utilizing stored tissue for long term fat grafting procedures in our clinics along with the ability to process the components of stored tissue for Regenerative Medicine uses in the future is a limitless opportunity."
"American CryoStem's entry into the Japanese market represents an extension of the Company's ongoing licensing and product distribution efforts into new markets. As the Japanese regenerative market continues to grow under its new regulatory guidelines, we expect increasing distribution of our products and services generating increased product sales in the new territory. Japan is a wonderful addition to our international sales and distribution strategy as we expand our global licensee and affiliate programs," stated Anthony Dudzinski, COO of American CryoStem.
About Cell Source
Founded in 2015, CellSource operates a clinical laboratory and multiple affiliated clinics for the aesthetic and regenerative medicine market in Japan. Located in Shibuya, Tokyo, CellSource will utilize the American CryoStem adipose tissue collection, processing and storage platform to standardize and the provide market with current and future tissue based services.
For more information please visit: http://www.cellsource.jp/
About American CryoStem Corporation
Founded in 2008, American CryoStem is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company has developed Standard Operating Procedures (SOPs) to operate a state-of-art, FDA-registered, clinical laboratory dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging platform technologies with 5+ developed products the Company is creating a global footprint of licensed laboratory affiliates and physicians networks to deliver current and future cellular applications.
The Company maintains a strategic portfolio of intellectual property that forms its standardized platform which supports a growing pipeline of stem cell applications and biologic products. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC products by combining its platform with synergistic technologies to create jointly developed applications and intellectual property.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.732-747-1007 or via email at NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...